Haemonetics Completes Sale of Complete Blood Belongings to GVS, S.p.A By Investing.com

BOSTON, Jan. 14, 2025 /PRNewswire/ — Haemonetics (NYSE:) Company (NYSE:  HAE),  a world medical know-how firm targeted on delivering revolutionary medical options to drive higher affected person outcomes, right this moment introduced that it has accomplished the beforehand introduced sale of its complete blood property to GVS, S.p.A (“GVS”), one of many world’s main producers of filter options for functions within the healthcare and life sciences sectors. In reference to the closing of this transaction, GVS has acquired Haemonetics’ portfolio of proprietary complete blood assortment, processing and filtration options, together with Haemonetics’ manufacturing facility in  Covina, California  the place sure of those merchandise are produced, and associated gear and property positioned at Haemonetics’ manufacturing facility in  Tijuana, Mexico.

The transaction contains a complete money consideration of as much as  $67.8M, together with  $45.3M  upfront after giving impact to sure customary changes, and as much as  $22.5M  in contingent earn-outs over the following 4 years. The Firm intends to make use of the proceeds from this transaction for normal company functions and extra investments in development initiatives. Haemonetics will present additional particulars relating to the monetary affect of this transaction on its fiscal yr 2025 steering throughout its third-quarter earnings name, scheduled for February 6, 2025, at 8:00 AM ET.

Haemonetics’ Blood Middle enterprise will proceed to fabricate and supply clients with its full line of apheresis options for automated blood assortment. These embrace units and disposable kits that help a wide range of apheresis collections, together with platelets, plasma and purple cells, and guarantee environment friendly blood middle operations.

ABOUT HAEMONETICS

Haemonetics (NYSE: HAE) is a world healthcare firm devoted to offering a set of revolutionary medical merchandise and options for purchasers, to assist them enhance affected person care and scale back the price of healthcare. Our know-how addresses necessary medical markets: blood and plasma part assortment, the surgical suite and hospital transfusion companies. To study extra about Haemonetics, go to  www.haemonetics.com.

Cautionary Notice Relating to Ahead-Wanting Statements

This press launch comprises forward-looking statements throughout the which means of Part 27A of the Securities Act of 1933 and Part 21E of the Securities Change Act of 1934. Ahead-looking statements don’t relate strictly to historic or present details and could also be recognized by way of phrases similar to “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “forecasts,” “foresees,” “potential” and different phrases of comparable which means along with statements relating to, amongst different issues, (i)  the anticipated advantages to Haemonetics arising from the completion of the transaction; (ii) statements relating to Haemonetics’ methods, positioning, assets, capabilities and expectations for future efficiency; and (iii) the assumptions underlying or regarding any such assertion. Such forward-looking statements usually are not meant to foretell or assure precise outcomes, efficiency, occasions or circumstances and might not be realized as a result of they’re based mostly upon Haemonetics’ present projections, plans, aims, beliefs, expectations, estimates and assumptions and are topic to a lot of dangers and uncertainties and different influences. Precise outcomes and the timing of sure occasions and circumstances could differ materially from these described by the forward-looking statements on account of these dangers and uncertainties.

Components which will affect or contribute to the inaccuracy of the forward-looking statements or trigger precise outcomes to vary materially from anticipated or desired outcomes could embrace, with out limitation, the failure to comprehend the anticipated advantages of the transaction, together with from non-achievement of any industrial milestone required to obtain all or a part of the extra contingent consideration, or the transaction having an unanticipated affect; Haemonetics’ means to foretell precisely the demand for its merchandise and merchandise below growth and to develop methods to handle its markets efficiently; and the affect of aggressive merchandise and pricing and technical improvements that would render merchandise marketed or below growth by Haemonetics out of date. These and different components are recognized and described in additional element in Haemonetics’ filings with the U.S. Securities and Change Fee. Haemonetics doesn’t undertake to replace these forward-looking statements.